Primary blast lung injury frequently complicates military conflict and terrorist attacks on civilian populations. The fact that it occurs in areas of conflict, or unpredictable mass casualty events makes clinical study in human casualties implausible. Research in this field is therefore reliant on the use of some form of biological or non-biological surrogate model. We briefly review the modelling work undertaken in this field to date and describe the rationale behind the generation of our in-silico physiological model.
Introduction
First described by Hooker in 1924(1) as a "single gross lesion found post mortem after exposure to air concussion due to high-explosive", primary blast lung injury (PBLI) is currently defined as "radiological and clinical evidence of acute lung injury occurring within 12 hours of exposure and not due to secondary or tertiary injury".(2) It is a disease characterized by intra-parenchymal haemorrhage, laceration and pneumothoraces.(3) In the absence of a specific biomarker or radiological hallmark, it can be difficult to distinguish PBLI with confidence from other forms of lung damage in complex patterns of injury. PBLI occurred in some 7% of UK casualties in the most recent conflict in Afghanistan despite the rudimentary nature of the opposition forces.(4) It is likely that PBLI will be an increasingly encountered by UK Defence Medical Services (DMS) in future more industrialised conflicts due to a combination of factors. Firstly, a more economically capable opponent will be equipped with the wide variety of thermobaric weaponry that is readily available and has been recently used in the Balkan and Chechnian conflicts.(5) Secondly, British military casualties exposed to such weapons are more likely to survive to reach hospital as improvements in personal protective equipment (6) and pre-hospital care reduces immediate fatalities due to penetrating injury. (7) There is thus a need to increase our understanding of the pathophysiology of this disease and to create accurate research models of PBLI.
Modelling based research
Modelling is the use of a surrogate entity to represent a complex system in a readily reproducible manner. Models can be either biological or non-biological. Biological models are further subdivided into in-vitro (cell culture), ex-vivo (live organ) or in-vivo (live animal).(8) Non-biological models are either computational ("in-silico") or physical (Anthropomorphic) surrogates of the biological system of interest.
As a research technique, the validity of modelling parallels that of clinical trials or laboratory study.(9) Non-biological based research is cheaper than animal modelling, requires less stringent ethical approval and can accommodate scenarios that are unachievable in live animal or human research (such as multiple casualty with multiple injury events). It can do this in an easily repeatable manner so that adequately powered studies which can achieve statistical significance can be undertaken. Modelling also facilitates the Ministry of Defence's ambition of limiting animal experimentation (10) and the impetus for the scientific community to "Replace, Reduce and Refine" when considering the use of live animals in research. (11, 12) Both biological and non-biological models of primary blast injury to the chest exist and are in use. The original biological PBLI modelling work of note was undertaken by Bowen and colleagues in 1968.(13) This frequently referenced work is still used as a benchmark comparator by subsequent researchers despite significant weaknesses.
Limitations include its use of a broad range of large and small animal species, the mixing of long and short duration blasts and the mixing of blast over-pressure measuring modalities (reflected and incident measurements differ significantly for any given explosion introducing significant differences in recorded over-pressure). This work suggests exposure injury and lethality thresholds, but having been undertaken almost 50 years ago does not reflect the significant advances in medical care achieved over this period. It also does not describe the severity of injury in survivors and the likely requirement for, and duration of, intensive care management. Blast injury research continues using both in-vivo and ex-vivo biological models.(14-16) Rodents are commonly used to model lung injury due to a variety of mechanisms including blast. The model assumes that a patient is mechanically ventilated and not contributing to respiratory effort. Both the cardiovascular and respiratory systems are divided into a series of individual components, each of which are described by a set of independent variables (Fig 2) . At the beginning of a modelling study, these variables are initially set so that they represent the patient population to be studied. Once initiated, the model For the model to be of relevance to the DMS we feel that it needs to meet several criteria. Primarily, it must be validated against the human injury experienced by UK service personnel suffering PBLI in combat. To this end we are creating a clinical database of UK PBLI victims generated in the recent conflict in Afghanistan which will be used to inform the model as to blast-dose related physiological effect and outcome.
We need to be able to utilise the model throughout the chain of care from the point of wounding to rehabilitation. It therefor needs to be able to accommodate the study of buddie-buddie care in a pre-hospital environment, potential medical interventions in a Role II/III emergency department and also a variety of ventilatory approaches whilst mechanically ventilated in intensive care. In order to achieve this several adaptions need to be made. It must be able to model spontaneous ventilation in the pre-hospital environment, the effect of possible modulators of pulmonary inflammation and biotrauma that could be administered both in the pre-hospital or emergency department and finally it should be able to replicate the consequences of intensive care management including ventilator induced lung injury (VILI), oxygen toxicity and a fluctuating fluid volume status. In addition to this we hope to make the software sensitive to the age and gender of the casualty.
Diagnostically we are concurrently developing computerised tomography (CT) criteria for identifying and quantifying PBLI. We are also in the early stages of attempting to identify potential mRNA based biomarkers for the disease. CT images consist of voxels (3-dimensional pixels), each of which can be interrogated for their density measured in Hounsfield units (HU).
Existing Imaging software (Analyze®) allows 3-D reconstructions of CT lung images from PBLI casualties to be created which only displays voxels from poorly or non-aerated lung tissue (voxel range of -250 to +250 HU; Figure. 3). This data can also be used to quantify the proportion of lung tissue that is poorly or non-aerated as a consequence of PBLI ( Figure. 4) .(31) Early evidence suggests that this method may prove useful in the identification of casualties with PBLI.(32) This work will be used to inform our computerised model of the proportion of non-functioning alveoli in our human casualties in order to increase its fidelity and clinical range.
Future direction.
Despite this extensive modeling activity, it has not kept pace with advances in medicine such as physician lead pre-hospital care, highly orchestrated and effective emergency department management of critically injured casualties, intensive care therapy and computed tomography imaging. It also fails to recognize the fact that improved prehospital care will result in increasingly severe cases of PBLI requiring management by the DMS. No model or measurable parameter exists that will either inform clinicians of the degree of injury resulting from shockwave exposure alone, can predict the ongoing physiological compromise surviving casualties will suffer or allow clinicians to model different treatment, mitigating or preventative strategies.(33) It is the ambition of our group to create a militarily relevant blast lung injury model validated against human combat injury and augmented by specific serological and CT markers of disease severity that will facilitate future research in this field.
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